/Genetically Engineered Human Fetal Liver Niche As Platform For Biomanufacturing Of Hematopoietic Stem Cells
Abstract

The present disclosure relates to methods for expanding populations of hematopoietic stem cells (HSCs) using a genetically engineered human fetal liver niche and compositions of purified ex vivo expanded HSCs. Also provided herein are methods of using such expanded HSC cell populations for clinical applications including allogeneic hematopoietic stem cell transplantation and for drug discovery and modeling human liver development.

Full Text

What is claimed is:

The present disclosure relates to methods for expanding populations of hematopoietic stem cells (HSCs) using a genetically engineered human fetal liver niche and compositions of purified ex vivo expanded HSCs. Also provided herein are methods of using such expanded HSC cell populations for clinical applications including allogeneic hematopoietic stem cell transplantation and for drug discovery and modeling human liver development.
Timeline
Filed
06/12/2026
Published
10/01/2026
Granted
Not Available
IPC Codes(4)
C12N 5/0789:Stem cells; Multipotent progenitor cells
A61K 35/28:Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
C07K 14/47:from mammals